Cryptococcal Meningitis in HIV-Negative Patients: A 12-Year Single-Center Experience in China
by
,
Yu Huang
1,2,
Xiaozhi Jin
1,2,
Faling Wu
1,2,
Tongtong Pan
1,
Xiaodong Wang
1,
Dazhi Chen
1,3,* and
Yongping Chen
1,2,* 1
Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China
2
Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China
3
Department of Clinical Medicine, Hangzhou Medical College, Hangzhou 310053, China
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(2), 515; https://doi.org/10.3390/jcm12020515
Submission received: 15 December 2022
/
Revised: 30 December 2022
/
Accepted: 6 January 2023
/
Published: 8 January 2023
(This article belongs to the Section Clinical Neurology)
Abstract
:Objective: Cryptococcal meningitis (CM) is a not rare condition in HIV-negative patients. Here, we describe the clinical characteristics, possible risk factors, and outcomes of HIV-negative patients with CM. Methods: Medical records from 99 HIV-negative patients with CM admitted to our hospital from 2010 to 2021 were reviewed systematically. We compared the clinical features and outcomes between patients with underlying diseases and otherwise healthy hosts. Results: The 99 HIV-negative CM patients had a mean age at presentation of 56.2 ± 16.2 years, and the female-to-male ratio was 77:22. A total of 52 (52.5%) CM patients had underlying conditions, and 47 patients (47.5%) had no underlying conditions. Kidney transplant represented the most frequent underlying condition (11.1%), followed by rheumatic disease (10.1%) and hematological diseases (9.1%). Compared to patients without underlying conditions, those with underlying conditions had significantly more fever, more steroid therapy, higher serum creatinine, and lower albumin, IgG, hemoglobin, and platelets (p < 0.05 for each). CM patients without underlying conditions had significantly more alcohol abuse than those with underlying conditions (31.9% vs. 9.6%, p = 0.011). By logistic regression analysis, male gender (OR = 3.16, p = 0.001), higher CSF WBC (OR = 2.88, p = 0.005), and protein (OR = 2.82, p = 0.002) were significantly associated with mortality. Conclusion: Patients with underlying conditions had a similar mortality to patients without underlying conditions. Alcohol abuse was a probable risk factor for CM for previously healthy patients. Male gender, higher CSF WBC, and protein were significantly associated with mortality.
1. Introduction
Cryptococcal meningitis (CM) is the leading cause of fungal meningitis in humans worldwide, especially in areas with a high prevalence of human immunodeficiency virus (HIV) [1,2]. CM is the second leading cause of HIV-related mortality, with the majority of deaths occurring in sub-Saharan Africa, where up to 60% of people with HIV reside [3]. In non-HIV endemic areas, CM is also present in a growing number of patients with natural or iatrogenic immunosuppression, with high rates of death despite therapy [4]. In the United States, deaths from non-HIV-related CM now account for approximately one-quarter of CM-related hospitalizations and one-third of CM-related deaths [5].
Nationally representative data show a decline in cryptococcal infections in developed nations with the advent of highly active antiretroviral therapy [5,6]. However, HIV-negative patients with cryptococcosis experience delayed diagnosis and have higher mortality rates than HIV-infected patients, affecting nearly 50% of all patients [7]. A US study reported the 90-day mortality rate of HIV-negative patients with CM as 27%, which is higher than that of HIV-positive patients, and a significant proportion of patients have no underlying conditions [8]. Despite some studies of CM in HIV-negative patients, the data from Asia are limited, especially in the past 10 years. In addition, the immunocompetent population accounts for an increasing proportion of morbidity, and much less has been written on the effects of lifestyle on the risk of CM in these patients [9,10].
We performed a retrospective observational study to describe the incidence, clinical features, prognostic and risk factors, and lifestyle of HIV-negative patients diagnosed with CM at a single center in China.
2. Patients and Methods
2.1. Patients
Patients hospitalized in the First Affiliated Hospital of Wenzhou University from January 2010 to December 2021 were selected for this retrospective study. Records of all of the patients with CM during a 12-year period were obtained.
This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (KY2022-R030). All of the enrolled patients signed informed consent forms. All methods were carried out in accordance with the relevant guidelines and regulations.
2.2. Diagnosis of CM
Cerebrospinal fluid (CSF) was routinely sent for complete white blood cell counts and differential counts, glucose, protein, and India ink stain and cultures. A definite diagnosis of CM was determined if the patient met at least one of the following criteria: (1) positive culture of Cryptococcus from CSF, (2) positive India ink smear of CSF centrifuged sediment for Cryptococcus. Immy Latex-Crypto Antigens (Immuno-Mycologics, Inc., Wenzhou, China) were used to perform the antigen assay in the blood or CSF, but not as a diagnostic criterion.
2.3. Clinical Profiles
Demographic characteristics of the study population were determined during the admission for incident CM. For each patient, the following data were obtained: demographic information, manifestations, underlying diseases (organ transplantation, autoimmune diseases, hematologic malignancies, primary nephrotic syndrome, cirrhosis, chronic renal failure, and solid malignancies), glucocorticoid therapy (defined as oral prednisone for at least three months in the past year), diabetes, laboratory data, including serum albumin, immunoglobulin G (IgG), serum creatinine, serum hemoglobin (Hb), white blood cells (WBC), and platelets, results of CSF analyses, magnetic resonance imaging (MRI), antifungal treatments, and patient outcomes. Chronic renal failure was defined as eGFR < 60 mL/min/1.73 m2. Patients underwent a lumbar puncture for CSF analysis and MRI at the time of diagnosis, and a repeat lumbar tap was performed if needed. Patient outcomes were short-term mortality, defined as death within 30 days of admission, and long-term mortality, defined as death before December 2021.
In addition, environmental exposures and lifestyle of CM patients were also recorded, including occupation, pet ownership, smoking, alcohol abuse, marijuana use, sleep late, sleep insufficiency, and living in a wet environment. We defined sleep late as going to sleep after 0 a.m., sleep insufficiency as sleeping less than 6 h per day, living in a wet environment as living on the first floor or basement, and alcohol abuse as drinking daily.
2.4. Statistical Analysis
Variables are described as the mean plus the standard deviation or proportion. Differences between patients in different groups were compared by the independent-sample t-test or chi-square test. Multivariate logistic regression was used to determine the independent clinical variables associated with CM patients who died. A p-value of <0.05 was considered statistically significant. All statistical analyses were performed using SPSS 22 (IBM, Cary, NC, USA).
3. Results
From January 2010 to December 2021, 106 cases of CM were documented. Among them, there were significantly more cases in non-HIV-infected patients (n = 99, 93.4%) than in HIV-infected patients (n = 7, 6.6%). There was a significantly increased trend in the incidence of non-HIV-infected patients but no significant trend in HIV-infected cases.
The 99 HIV-negative CM patients had a mean age at presentation of 56.2 ± 16.2 years, and the female-to-male ratio was 77:22. A total of 52 (52.5%) CM patients had underlying conditions, and 47 patients (47.5%) had no underlying conditions. The most common clinical manifestation was headache in 60 patients (60.6%), followed by fever in 51 patients (51.5%), and coma in 8 patients (8.1%). Lumbar punctures were performed at baseline in all patients, the culture of CSF for Cryptococcus was positive for 88 (88%) patients, and India ink preparations were positive for 49 (49%) patients. CSF or blood latex agglutination cryptococcal antigen titer (LACT) of more than 1:512 were demonstrated in 64 (64%) and 62 (62%) patients, respectively. MRI scans detected local lesions in 24 (24%) patients; local lesions were characterized by a low signal in T1, a high signal in T2, and FLARE in MRI, with or without enhancement. Compared to patients without underlying conditions, those with underlying conditions had significantly more fevers, more steroid therapy, higher serum creatinine, and lower albumin, IgG, hemoglobin, and platelets (p < 0.05 for all). However, there were no statistically significant differences in gender, age, diabetes, MRI abnormality, CSF examination, and antifungal therapy. The death rate was 23.1% in CM patients with underlying conditions and 21.3% in CM patients without underlying conditions (Table 1). The initial therapy involved intravenous amphotericin B and flucytosine combination for 79 (79%) patients and fluconazole or voriconazole alone for 20 (21%) patients. The K-M survival analysis indicated the mortality was similar between CM patients with and without underlying conditions (Figure 1).
Underlying conditions in the 99 HIV-negative patients who developed CM are listed in Table 1. Kidney transplant represented the most frequent underlying condition (11.1%), followed by rheumatic disease (10.1%), hematological system diseases (9.1%), chronic renal failure (8.1%), and cirrhosis (7.1%). Among the nearly 200,000 hospitalizations coded each year in our hospital during the study period, the total number of patients per underlying condition is shown in Table 2. Data on some conditions were not reliable, either because no specific code exists, because of overlap with other diseases, or because the code was created only recently. Hence, the incidence rates of CM could not be estimated for these conditions.
Environmental exposures and the lifestyle of these patients are shown in Table 3. CM patients without underlying conditions had significantly more alcohol abuse than those with underlying conditions (31.9% vs. 9.6%, p = 0.011). However, there were no significant differences between the two groups in terms of occupation, pet ownership, smoking, marijuana use, sleep late, sleep insufficiency, and living in a wet environment.
A total of 22 patients died within 30 days of admission, and the 30-day mortality was 22.2%. In the other 77 patients who were alive 30 days after admission at the time of the last follow-up, the median follow-up time was 44.3 months (range: 1–110 months). Among these 77 patients, 8 patients died after discharge during the follow-up period. Three patients died of reinfection at 5 months, 1 year, and 4 years, respectively, two patients died of heart failure at 8 months, and two patients died of a stroke at 1 month and 4 years, respectively. We also analyzed possible factors associated with mortality between surviving CM patients and deceased CM patients (Table 4). We found that deceased patients were significantly older, more likely to be male, and had higher WBC, CSF WBC, and CSF protein, and lower CSF chloride than surviving patients (p < 0.05 for all). By logistic regression analysis, male gender (OR = 3.16, p = 0.001), higher CSF WBC (OR = 2.88, p = 0.005), and protein (OR = 2.82, p = 0.002) were significantly associated with mortality (Table 5).
4. Discussion
In this retrospective study, data on 99 HIV-negative patients who developed CM were analyzed. Underlying conditions were present in 52.5% of the CM patients, and 47.5% of patients had no underlying conditions. Kidney transplant represented the most frequent underlying condition (11.1%), followed by rheumatic disease and hematological diseases. These findings are similar to those of some previous studies [9,10]. In a study at 15 medical centers in the United States of 306 HIV-negative patients with C. neoformans, 157 had central nervous system involvement, and 79% had a significant underlying condition; the most frequent underlying condition was chronic hepatic failure (16%), followed by solid-organ transplant and hematologic malignancy [9]. In a Chinese study, Zhu et al. reviewed 154 non-HIV-infected patients with CM, the majority of whom were otherwise apparently healthy (66.9%) [10].
The estimated incidence of underlying conditions in non-HIV-infected CM patients in our study varied broadly. The most frequent was kidney transplant (30 cases per 100,000 patient-year), followed by SLE, thrombocytopenic purpura, and primary nephrotic syndrome. Data about the incidence of CM in patients with different underlying conditions is limited. CM in previously healthy individuals is relatively rare, with approximately 3000 cases reported annually in the United States, which would put the incidence at approximately one in 100,000 individuals per year [11]. In two studies of SLE patients with central nervous system infections, the estimated incidence of CM was 13.8–44 cases per 100,000 patient-years [12,13]. Wu et al. examined the incidence and clinical features of CM among different groups of organ transplant patients, and the estimated incidence of CM was 32.9 cases per 100,000 patient-year [14]. These data indicated that patients with kidney transplant and SLE had a higher risk of CM than those with other underlying conditions.
Despite underlying conditions, the mortality of these patients for one month was close to that of patients without underlying conditions in our study. Zhu et al. retrospectively reviewed 154 non-HIV-infected patients with CM and also found that previously healthy patients had a similar treatment response and one-year survival as immunocompromised patients [10]. In a study of 34 HIV-negative children with CM in Beijing, those with no identifiable underlying disease had a similar prognosis both at discharge and follow-up to patients with underlying diseases [15]. In another study, George et al. also found that the mortality rate was similar between HIV-negative CM patients with or without solid organ transplant [16]. These findings indicated that CM without underlying conditions had a higher mortality rate, similar to that of patients with underlying conditions. Maybe the reason that previously healthy patients for whom diagnosis was delayed had more severe disease, and experienced more brain herniation, coma, seizures, hydrocephalus, and more surgical shunt procedures. In addition, post-infectious inflammatory response syndrome (PIIRS) has been reported as a deterioration in neurological status in a previously healthy patient with CM after CSF fungal culture conversion to negative following optimal treatment [17,18].
Although the risk factors for CM in immunocompromised hosts are well described and associated with the net state of immunosuppression, much less is known about the effects of occupation and lifestyle on the risk of CM in the general population. We found that CM patients without underlying conditions had significantly more alcohol abuse than those with underlying conditions, which indicates that alcohol abuse is a probable risk factor for CM in previously healthy patients. Alcohol abuse has been associated with invasive fungal infections, especially in patients with alcoholic cirrhosis [19]. Although no case-control studies have been reported to date, all of the patients that have been described had no other risk factor for invasive fungal infections except that of alcohol abuse. Spontaneous peritonitis due to C. neoformans has been described in patients with decompensated alcoholic cirrhosis and ascites [20].
We found that patients who died were significantly older, more likely to be male, had higher WBC, CSF WBC, and CSF protein, and lower CSF chloride than patients who survived. This was similar to some, but not all, previous studies. Guo et al. reviewed 34 HIV-negative children with CM, the patients in the survival group had higher ESR and eosinophil than patients in the death group, and there were no significant differences in age, area, contact history, time to diagnosis, hospitalization, and CSF tests [15]. In another retrospective study, a total of 126 CM and 105 tuberculous meningitis patients were included; multivariate analysis showed that older age, altered mentation, lower CD4/CD8 ratios, and higher CSF cryptococcal antigen were independent risk factors for poor prognosis for CM patients [21]. In an early study, 88 patients with CM were identified, and 37 (42%) were HIV-infected; they found patients who died had significantly lower CSF WBC, but this study contained HIV-positive patients, whom themselves had lower CSF WBC than HIV-negative patients [22]. In a recent study, early clinical and microbiological predictors of outcome in hospitalized patients with CM were evaluated [23], and older age and quantitative CSF yeast counts performed by direct microscopic exam were associated with mortality in multiple analyses by logistic regression [23]. We also found that male gender was significantly associated with mortality. This was not consistent with previous studies, although they also found more male patients in the groups that died compared to the groups that survived (9,10,23). These discrepancies may be due to differences in the characteristics of the studied population.
There were limitations in the present study. First, our study was retrospective research. Usually, there are missing data and misclassification in this kind of study. Second, the sample size was a limiting factor that may have affected the precision of the estimates. Finally, because of some missing data in the long-time follow-up, the long-term risk factors associated with mortality could not be fully determined.
In summary, we described the clinical characteristics and risk factors of HIV-negative CM patients. The main findings were that kidney transplant represented the most frequent underlying condition. Patients with kidney transplant and SLE had a higher risk factor of CM than those with other underlying conditions. Mortality during one month among patients with underlying conditions was similar to that among patients without underlying conditions in our study. Alcohol abuse was a probable risk factor of CM for previously healthy patients, and male gender, higher CSF WBC, and protein were significantly associated with mortality.
Author Contributions
X.J., Y.H. and F.W. contributed to the conception and design of the study and wrote the first draft of the manuscript. X.J. and Y.H. organized the database. T.P. performed the statistical analysis. X.W., D.C. and Y.C. revised the manuscript for intellectual content and English editing. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by grants from: the National Natural Science Foundation of China (82070593); Natural Science Foundation of Zhejiang Province (LD21H030002 and LQ17H030005); Public Welfare Science and Technology Project of Wenzhou (ZY2019008 and Y2020267); Major science and technology plan of Zhejiang Province (WKJ-ZJ-2318).
Institutional Review Board Statement
The study was approved by the Ethics Committee of First Affiliated Hospital of Wenzhou Medical University (ethical approval number: KY2022-R150).
Informed Consent Statement
All enrolled patients signed the informed consent forms.
Conflicts of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- Jarvis, J.N.; Meintjes, G.; Williams, A.; Brown, Y.; Crede, T.; Harrison, T.S. Adult meningitis in a setting of high HIV and TB prevalence: Findings from 4961 suspected cases. BMC Infect. Dis. 2010, 10, 67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tenforde, M.W.; Mokomane, M.; Leeme, T.; Tlhako, N.; Tsholo, K.; Ramodimoosi, C.; Dube, B.; MokoBela, K.O.; Tawanana, E.; Chebani, T.; et al. Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey. J. Infect. 2019, 79, 212–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rajasingham, R.; Smith, R.M.; Park, B.J.; Joseph, N.J.; Nelesh, P.G.; Tom, M.C.; David, W.D.; Loyse, A.; Boulare, D.R. Global Burden of Disease of HIV-Associated Cryptococcal Meningitis: An Updated Analysis. Lancet Infect. Dis. 2017, 17, 873–881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsai, W.-C.; Lien, C.-Y.; Lee, J.-J.; Wen, C.-H.; Chi, R.-H.; Nai, W.-T.; Chang, C.-C.; Lu, C.-H.; Chang, W.-N. The clinical characteristics and therapeutic outcomes of cryptococcal meningitis in elderly patients: A hospitalbased study. BMC Geriatr. 2019, 19, 91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pyrgos, V.; Seitz, A.E.; Steiner, C.A.; Prevots, D.R.; Williamson, P.R. Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS ONE 2013, 8, e56269. [Google Scholar] [CrossRef] [Green Version]
- van Elden, L.J.; Walenkamp, A.M.; Lipovsky, M.M.; Reiss, P.; Meis, J.F.; de Marie, S.; Dankert, J.; Hoepelman, A.I.M. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000, 14, 2787–2788. [Google Scholar] [CrossRef]
- Bratton, E.W.; Husseini, N.E.; Chastain, C.A.; Lee, M.S.; Poole, C.; Stürmer, T.; Juliano, J.J.; Weber, D.J.; Perfect, J.R. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS ONE 2012, 7, e43582. [Google Scholar] [CrossRef]
- Brizendine, K.D.; Baddley, J.W.; Pappas, P.G. Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune Status. PLoS ONE 2013, 8, e60431. [Google Scholar] [CrossRef] [Green Version]
- Pappas, P.G.; Perfect, J.R.; Cloud, G.A.; Larsen, R.A.; Pankey, G.A.; Lancaster, D.J.; Henderson, H.; Kauffman, C.A.; Haas, D.W.; Saccente, M.; et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 2001, 33, 690–699. [Google Scholar] [CrossRef] [Green Version]
- Zhu, L.-P.; Wu, J.-Q.; Xu, B.; Ou, X.-T.; Zhang, Q.-Q.; Weng, X.-H. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007. Med. Mycol. 2010, 48, 570–579. [Google Scholar] [CrossRef]
- Williamson, P.R.; Jarvis, J.N.; Panackal, A.A.; Fisher, M.C.; Molloy, S.F.; Loyse, A.; Harrison, T.S. Cryptococcal meningitis: Epidemiology, immunology, diagnosis and therapy. Nat. Rev. Neurol. 2017, 13, 13–24. [Google Scholar] [CrossRef]
- Hung, J.-J.; Ou, L.-S.; Lee, W.-I.; Huang, J.-L. Central nervous system infections in patients with systemic lupus erythematosus. J. Rheumatol. 2005, 32, 40–43. [Google Scholar]
- Vargas, P.J.; King, G.; Navarra, S.V. Central nervous system infections in Filipino patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 2009, 12, 234–238. [Google Scholar] [CrossRef]
- Wu, G.; Vilchez, R.; Eidelman, B.; Fung, J.; Kormos, R.; Kusne, S. Cryptococcal meningitis: An analysis among 5521 consecutive organ transplant recipients. Transpl. Infect. Dis. 2002, 4, 183–188. [Google Scholar] [CrossRef] [PubMed]
- Guo, L.-Y.; Liu, L.-L.; Liu, Y.; Chen, T.-M.; Li, S.-Y.; Yang, Y.-H.; Liu, G. Characteristics and outcomes of cryptococcal meningitis in HIV seronegative children in Beijing, China, 2002–2013. BMC Infect. Dis. 2016, 16, 635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- George, I.A.; Spec, A.; Powderly, W.; Santos, C.A.Q. Comparative Epidemiology and Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ Transplant Associated Cryptococcosis: A Population-Based Study. Clin. Infect. Dis. 2018, 66, 608–611. [Google Scholar] [CrossRef] [PubMed]
- Anjum, S.; Williamson, P.R. Clinical aspects of immune damage in cryptococcosis. Curr. Fungal Infect. Rep. 2019, 13, 99–108. [Google Scholar] [CrossRef]
- Anjum, S.; Dean, O.; Kosa, P.; Magone, M.T.; King, K.A.; Fitzgibbon, E.; Kim, H.J.; Zalewski, C.; Murphy, E.; Billioux, B.J.; et al. Outcomes in Previously Healthy Cryptococcal Meningoencephalitis Patients Treated With Pulse Taper Corticosteroids for Post-infectious Inflammatory Syndrome. Clin. Infect. Dis. 2021, 73, e2789–e2798. [Google Scholar] [CrossRef]
- Sipsas, N.V.; Kontoyiannis, D.P. Occupation, lifestyle, diet, and invasive fungal infections. Infection 2008, 36, 515–525. [Google Scholar] [CrossRef]
- Albert, B.S.; Venema, F.; Bausch, J.; Hunfeld, K.P.; Schäfer, V. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: Case report and review of the literature. Infection 2005, 33, 282–288. [Google Scholar] [CrossRef]
- Qu, J.; Zhou, T.; Zhong, C.; Deng, R.; Lü, X. Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: A retrospective study. BMC Infect. Dis. 2017, 17, 51. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.-C.; Wang, J.-T.; Sun, H.-Y.; Chen, Y.-C. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J. Microbiol. Immunol. Infect. 2011, 44, 338–345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Oliveira, L.; Melhem, M.S.C.; Buccheri, R.; Chagas, O.J.; Vidal, J.E.; Diaz-Quijano, F.A. Early clinical and microbiological predictors of outcome in hospitalized patients with cryptococcal meningitis. BMC Infect. Dis. 2022, 22, 138. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Comparison of the mortality between CM patients with and without underlying conditions. Group 1: Patients without underlying conditions; Group 2: Patients without underlying conditions.
Figure 1.
Comparison of the mortality between CM patients with and without underlying conditions. Group 1: Patients without underlying conditions; Group 2: Patients without underlying conditions.
Table 1.
Clinical characteristics of cryptococcal meningitis (CM) patients with and without underlying conditions (n = 99).
Table 1.
Clinical characteristics of cryptococcal meningitis (CM) patients with and without underlying conditions (n = 99).
| Variables | CM with Underlying Conditions (n = 52) | CM without Underlying Conditions (n = 47) | p-Value |
|---|---|---|---|
| Male (n, %) | 12 (23.1) | 10 (21.3) | 0.830 |
| Age (years) | 57.1 ± 16.2 | 55.1 ± 16.3 | 0.535 |
| Headache (n, %) | 28 (53.8) | 32 (68.1) | 0.148 |
| Fever (n, %) | 32 (61.5) | 19 (40.4) | 0.036 * |
| Coma (n, %) | 3 (5.8) | 5 (10.6) | 0.375 |
| Pulmonary Cryptococcosis (n, %) | 15 (28.8) | 10 (21.3) | 0.387 |
| Encephalitis (n, %) | 3 (5.8) | 4 (8.5) | 0.595 |
| Cryptococcal septicemia (n, %) | 6 (11.5) | 4 (8.5) | 0.618 |
| History of steroid therapy (n, %) | 35 (67.3) | 2 (4.3) | <0.001 * |
| Diabetes (n, %) | 12 (23.1) | 10(21.3) | 0.830 |
| Albumin (g/L) | 33.9 ± 6.2 | 37.5 ± 5.7 | 0.006 * |
| IgG (g/L) | 9.3 ± 4.0 | 13.4 ± 10.4 | 0.017 * |
| Serum creatinine (μmol/L) | 111.4 ± 109.1 | 62.9 ± 22.0 | 0.005 * |
| Hemoglobin (g/dL) | 109.6 ± 23.6 | 126.1 ± 20.5 | 0.001 * |
| WBC (109/L) | 7.6 ± 4.6 | 8.0 ± 3.2 | 0.613 |
| Platelet (109/L) | 192.6 ± 87.0 | 245.2 ± 84.1 | 0.004 * |
| ESR (mm/h) | 21.5 ± 18.3 | 20.7 ± 17.8 | 0.851 |
| CRP (mg/L) | 23.3 (1.1–92.9) | 19.1 (0.28–107.0) | 0.400 |
| Procalcitonin (ng/mL) | 0.46 (0–6.5) | 0.2 (0–1.5) | 0.175 |
| CD4+ cell count (cells/mm3) | 302.0 ± 187.6 | 309.3 ± 240.7 | 0.918 |
| CD8+ cell count (cells/mm3) | 490.8 (23–495) | 266.8 ± 138.6 | 0.188 |
| NK cell count (cells/mm3) | 164.8 ± 157.3 | 156.6 ± 151.1 | 0.887 |
| CSF opening pressure (cmH2O) | 225.2 ± 97.8 | 240.8 ± 108.7 | 0.517 |
| CSF WBC (cell/mm3) | 330.7 (0–9800) | 185.2 (0–2160) | 0.507 |
| CSF protein (g/L) | 2.4 (0.3–33.5) | 1.5 (0.1–9.1) | 0.329 |
| CSF glucose (mmol/L) | 2.7 ± 1.7 | 2.6 ± 1.4 | 0.754 |
| CSF chloride (mmol/L) | 117.3 ± 6.9 | 116.1 ± 7.2 | 0.424 |
| MRI abnormality (n, %) | 11 (21.2) | 13 (27.7) | 0.451 |
| Therapy | |||
| Amphotericin B + flucytosine (n, %) | 38 (73.1) | 41 (87.2) | 0.080 |
| Fluconazole or Voriconazole (n, %) | 14 (26.9) | 6 (12.8) | 0.080 |
| Died (%) | 12 (23.1) | 10 (21.3) | 0.830 |
WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging. Data are shown as the mean ± SD (standard deviation) or the percentages. * p < 0.05.
Table 2.
Main underlying conditions in 99 consecutive cases of cryptococcal meningitis (CM) in non-HIV-infected patients, and the number of patients hospitalized with this condition (2010–2021).
Table 2.
Main underlying conditions in 99 consecutive cases of cryptococcal meningitis (CM) in non-HIV-infected patients, and the number of patients hospitalized with this condition (2010–2021).
| Underlying Condition | Number of CM (% of Total Cases in Non-HIV Patients) | Total Number of Patients with the Underlying Condition |
|---|---|---|
| Kidney transplant | 11 (11.1%) | 3048 |
| Rheumatic disease | 10 (10.1%) | |
| Systemic lupus erythematosus | 8 | 6934 |
| Rheumatoid arthritis | 1 | 11828 |
| Giant cell arteritis | 1 | 22 |
| Hematological system diseases | 9 (9.1%) | |
| Leukemia | 3 | 6170 |
| Lymphoma | 1 | 8412 |
| Multiple myeloma | 1 | 2086 |
| Myelodysplastic syndrome | 1 | 1788 |
| Thrombocytopenic purpura | 2 | 2421 |
| Autoimmune hemolysis | 1 | 2086 |
| Primary nephrotic syndrome | 5 (5%) | 8277 |
| Cirrhosis | 7 (7.1%) | |
| Chronic renal failure | 8 (8.1%) | |
| Solid tumors | 2 (2.0%) | |
| Breast cancer | 1 | |
| Thymoma | 1 | |
| None | 47 (47.0%) |
Table 3.
Environmental exposures and lifestyle of CM patients with and without underlying conditions (n = 99).
Table 3.
Environmental exposures and lifestyle of CM patients with and without underlying conditions (n = 99).
| Variables | CM with Underlying Conditions (n = 52) | CM without Underlying Conditions (n = 47) | p-Value |
|---|---|---|---|
| Farmer (n, %) | 3 (5.8) | 4 (8.5) | 0.705 |
| Construction workers (n, %) | 2 (3.8) | 4 (8.5) | 0.419 |
| Landscapers (n, %) | 1 (1.9) | 2 (4.3) | 0.603 |
| Pet ownership (n, %) | 3 (5.8) | 4 (8.5) | 0.705 |
| Smoking (n, %) | 10 (19.2) | 12 (25.5) | 0.478 |
| Alcohol abuse (n, %) | 5 (9.6) | 15 (31.9) | 0.011 * |
| Marijuana use (n, %) | 1 (1.9) | 1 (2.1) | 1.000 |
| Sleep late (n, %) | 15 (28.8) | 19 (40.4) | 0.290 |
| Sleep insufficiency (n, %) | 21 (40.4) | 26 (55.3) | 0.161 |
| Living in wet environment (n, %) | 5(9.6) | 8 (17.0) | 0.374 |
| Tourism in the past 3 months (n, %) | 1 (1.9) | 2 (4.3) | 0.603 |
CM, cryptococcal meningitis; * p < 0.05.
Table 4.
Possible risk factors associated with mortality between surviving CM patients and deceased CM patients (n = 99).
Table 4.
Possible risk factors associated with mortality between surviving CM patients and deceased CM patients (n = 99).
| Variables | Surviving Patients (n = 77) | Deceased Patients (n = 22) | p-Value |
|---|---|---|---|
| Male (n, %) | 10 (13.0) | 12 (54.5) | <0.001 * |
| Age | 54.5 ± 15.8 | 62.1 ± 16.5 | 0.043 * |
| Coma (n, %) | 5 (6.5) | 3 (13.6) | 0.278 |
| Pulmonary cryptococcosis (n, %) | 21 (27.3) | 4 (18.2) | 0.387 |
| Encephalitis (n, %) | 4 (5.2) | 3 (13.6) | 0.173 |
| Cryptococcal septicemia (n, %) | 7 (9.1) | 3 (13.6) | 0.533 |
| History of steroid therapy (n, %) | 30 (39.0) | 7 (31.8) | 0.541 |
| Underlying conditions (n, %) | 43 (55.8) | 9 (40.9) | 0.216 |
| Kidney transplant (n, %) | 11 (14.3) | 0 (0) | 0.060 |
| Rheumatic disease (n, %) | 7 (9.1) | 3 (13.6) | 0.533 |
| Hematological diseases (n, %) | 8 (10.4) | 1 (4.5) | 0.400 |
| Primary nephrotic syndrome (n, %) | 4 (5.1) | 1 (4.5) | 0.921 |
| Chronic hepatic failure (n, %) | 4 (5.1) | 2 (9.1) | 0.480 |
| Chronic renal failure (n, %) | 5 (6.5) | 2 (9.1) | 0.675 |
| Albumin (g/L) | 35.6 ± 6.6 | 35.1 ± 4.9 | 0.739 |
| IgG (g/L) | 10.9 ± 7.8 | 9.7 ± 2.4 | 0.565 |
| Serum creatinine (μmol/L) | 98.3 ± 93.8 | 57.5 ± 22.7 | 0.052 |
| Hemoglobin (g/dL) | 116.6 ± 23.5 | 119.0 ± 24.1 | 0.678 |
| WBC (109/L) | 7.3 ± 3.5 | 9.4 ± 5.3 | 0.042 * |
| Platelet (109/L) | 216.5 ± 81.9 | 217.2 ± 113.4 | 0.973 |
| ESR (mm/h) | 21.2 ± 18.8 | 21.0 ± 13.8 | 0.973 |
| CRP (mg/L) | 19.4 (0.28–107) | 27.6 ± 22.9 | 0.182 |
| Procalcitonin (ng/mL) | 0.33 (0–6.5) | 0.42 (0–3.1) | 0.718 |
| CD4+ cell count (cells/mm3) | 407.6 ± 327.2 | 180 ± 177.7 | 0.305 |
| CD8+ cell count (cells/mm3) | 431.7 ± 392.1 | 247.5 ± 110.6 | 0.467 |
| NK cell count (cells/mm3) | 171.2 ± 160.2 | 94 ± 90.4 | 0.360 |
| CSF opening pressure (cmH2O) | 227.7 ± 96.4 | 260.5 ± 133.6 | 0.317 |
| CSF WBC (cell/mm3) | 138.2 (0–2160) | 774.6 (0–9800) | 0.019 * |
| CSF protein (g/L) | 1.4 ± 1.2 | 4.4 (0.1–33.5) | 0.008 * |
| CSF glucose (mmol/L) | 2.7 ± 1.2 | 2.5 ± 1.6 | 0.631 |
| CSF chloride (mmol/L) | 117.6 ± 7.2 | 112.8 ± 4.6 | 0.011 * |
| MRI abnormality (n, %) | 20 (26.0) | 4 (18.2) | 0.452 |
| Therapy | |||
| Amphotericin B + flucytosine (n, %) | 61 (79.2) | 18 (81.8) | 0.789 |
| Fluconazole or Voriconazole (n, %) | 16 (20.8) | 4 (18.2) | 0.789 |
CM, cryptococcal meningitis; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging. Data are shown as the mean ± SD (standard deviation) or the percentages. * p < 0.05.
Table 5.
Logistic regression analysis with outcomes as the dependent variable (R2 = 0.68). OR, odds ratios; CI, confidence interval; cerebrospinal fluid; WBC, white blood cell; CSF.
Table 5.
Logistic regression analysis with outcomes as the dependent variable (R2 = 0.68). OR, odds ratios; CI, confidence interval; cerebrospinal fluid; WBC, white blood cell; CSF.
| Variable | OR | 95% CI for OR | p-Value |
|---|---|---|---|
| Male | 3.16 | 2.11–12.63 | 0.001 |
| CSF WBC | 2.88 | 1.60–14.90 | 0.005 |
| CSF protein | 2.82 | 1.82–12.79 | 0.002 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Huang, Y.; Jin, X.; Wu, F.; Pan, T.; Wang, X.; Chen, D.; Chen, Y. Cryptococcal Meningitis in HIV-Negative Patients: A 12-Year Single-Center Experience in China. J. Clin. Med. 2023, 12, 515. https://doi.org/10.3390/jcm12020515
AMA Style
Huang Y, Jin X, Wu F, Pan T, Wang X, Chen D, Chen Y. Cryptococcal Meningitis in HIV-Negative Patients: A 12-Year Single-Center Experience in China. Journal of Clinical Medicine. 2023; 12(2):515. https://doi.org/10.3390/jcm12020515
Chicago/Turabian StyleHuang, Yu, Xiaozhi Jin, Faling Wu, Tongtong Pan, Xiaodong Wang, Dazhi Chen, and Yongping Chen. 2023. "Cryptococcal Meningitis in HIV-Negative Patients: A 12-Year Single-Center Experience in China" Journal of Clinical Medicine 12, no. 2: 515. https://doi.org/10.3390/jcm12020515
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
